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Abstract The murine monoclonal antibody REGA-3G12 selec-
tively and specifically inhibits the activity of human gelatinase B. 
The cDNA fragments which encode the variable regions of the 
light and heavy chains were isolated by PCR-mediated cloning 
and sequenced. Single-chain Fv expression constructs for 
Escherichia coli were generated in which c-myc tag sequences 
were encoded. Inducible expression of the scFv and secretion to 
the periplasm were obtained with higher yields when the c-myc 
tag sequence was positioned at the amino-terminal side. The 
inhibitory activity of purified scFv on neutrophil gelatinase B was 
tested in a gelatin degradation assay and it was found to possess 
a similar specific activity as that of the intact monoclonal 
antibody and of the pepsin-clipped F(ab')2 derivative. This shows 
for the first time that inhibition of soluble enzymes with scFv is 
possible and opens new perspectives for the treatment of diseases 
with excessive and detrimental enzyme production in the host. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Matrix metalloproteinases (MMPs) have been recognized as 
key players in physiological tissue remodelling and in pathol-
ogies including cancer cell invasion, metastasis [1,2] and auto-
immune diseases [3]. Several control levels of MMP activity 
exist in vivo: regulation of gene transcription, secretion, acti-
vation and specific inhibition [4]. Excessive production of the 
inducible gelatinase B has been observed in a number of dis-
eases [5-8] and inhibition of gelatinase B may become a ther-
apy for autoimmune disorders, such as rheumatoid arthritis 
and multiple sclerosis [3], and for invasive cancers [8]. The 
latter enzyme constitutes an essential step in the chain of 
matrix remodelling [3,9] and experiments in animals have 
shown that blockade of metalloproteinases has disease-limit-
ing effects [10-12]. Inhibitory antibodies, however, have not 
yet been used in such blockade experiments. 
Unfortunately, the so far identified low molecular weight 
inhibitors of gelatinase B (e.g. tetracyclines) possess low selec-
tivity and specificity [13]. Even the natural tissue inhibitors of 
metalloproteinases (TIMPs) are not selective for one particu-
lar enzyme but may inhibit various collagenases, stromelysins, 
membrane-type metalloproteinases and gelatinases. Therefore, 
more specific and potent novel inhibitor types are currently 
being developed. 
The most specific inhibitor of human gelatinase B known to 
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date is a monoclonal antibody, REGA-3G12. It binds with 
high affinity (Kd =2.1 X 10"9 M) to and inhibits the biological 
activity of gelatinase B, but not of gelatinase A [14]. The 
production of the inhibitory antibody REGA-3G12 and re-
lated monoclonals, and preferentially the engineering of de-
rivatives, is essential for further biochemical and biological 
evaluation as specific inhibitors of gelatinase B in animal or 
human disease models. 
For the application of gelatinase B-inhibitory monoclonals 
in patients, derivatization is necessary to minimize the human 
anti-mouse antibody (HAMA) response [15]. This may be 
achieved, for instance, by generating humanized antibodies 
or antibody fragments, by the production of human hybrid-
omas or by in vitro immunization. Alternatively, transgenic 
human antibodies might be produced by the recently de-
scribed expression of the megabase human light and heavy 
chain loci in the form of YAC clones in the mouse [16]. For 
particular immunodiagnostic and immunotherapeutic use in 
vivo, small antibody derivatives are desirable because of their 
shorter half-life (rapid clearance of diagnostic probes) and 
faster tissue penetration when compared to the intact human-
ized antibodies. In particular, the effector functions of the 
constant domains of the immunoglobulins, e.g. complement 
activation and the binding to Fc receptors, are superfluous for 
antibodies against soluble molecules (e.g. hormones, cyto-
kines, neurotransmitters and enzymes). Indeed, the antigen-
recognizing and inhibitory functions of the variable domains 
of the light and heavy chains, when appropriately folded and 
associated, may well replace the intact immunoglobulin. In 
addition, the avidity effect does not play a role in the binding 
to soluble antigens. Here, we describe the cloning, construc-
tion and characterization of a single-chain Fv with inhibitory 
activity against gelatinase B. 
2. Materials and methods 
2.1. Cell lines and expression vectors 
REGA-3G12 is a murine hybridoma that secretes a monoclonal 
antibody against natural human neutrophil gelatinase B [14]. The 
MYC1-9E10.2 (ATCC CRL 1729) hybridoma produces a murine 
mAb (9E10) that recognizes part of the human c-myc protein. The 
mAb (9E10) facilitates the detection and purification of expression 
products containing the c-myc polypeptide. The expression vector 
pHENl [17] was kindly provided by Dr. G. Winter (MRC, Cam-
bridge, UK). The vectors pscFv-D9D10 [18] and pscFv-D9D10-
GF311 were constructed in our laboratory. The scFv genes are under 
the control of the lacZ promoter, the products are secreted into the 
periplasm with the help of the hydrophobic pelB signal peptide. 
2.2. Cloning and sequencing of the variable heavy ( VH) and light ( VK) 
chain genes 
Total cellular RNA was extracted from the hybridoma cells 
(REGA-3G12) by the TRIzol reagent (Life Technologies, Gaithers-
burg, MD) and 1 μg was used for first strand cDNA synthesis in a 
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50 μΐ reaction mixture containing 1 XRT buffer (0.14 M KC1, 8 mM 
MgCl2, 50 mM Tris-HCl pH 8.1), 25 mM DTT, 0.15 mM dNTP, 1 μg 
random primers (Life Technologies), 50 U human placental ribonu-
clease inhibitor and 4 U RAV-2 reverse transcriptase (both from 
Amersham, Buckinghamshire, UK). The reaction mixture was kept 
at 23°C for 10 min followed by an incubation step of 60 min at 
42°C. The enzyme was inactivated by a heating step of 5 min at 95°C. 
For the amplification of VH and VK gene segments by PCR, 2.5 μΐ 
of the cDNA mixture was subjected to 35 cycles using the VH-specific 
primers VH1FOR-2 and VH1BACK [19] and the VK-specific primers 
VK2FOR and VK2BACK (sequences obtained from Dr. Winter, 
MRC. Cambridge, UK and also described in [18]), respectively. 
Each PCR cycle consisted of denaturation at 95°C for 35 s, annealing 
at 60°C (for VH) or 55°C (for VK) for 50 s, and extension at 72°C for 
35 s, with a 10 min final extension using Ultma DNA polymerase 
(Perkin Elmer, Foster City, CA). The amplified VH and VK gene 
fragments were purified out of a 2.0% agarose gel with the QIAquick 
kit (Qiagen, Hilden, Germany). The purified VH and VK gene frag-
ments were digested with BstEU-Pstl and Xhol-Sacl, respectively, and 
inserted into the appropriate plasmid vectors (pEG04 and pBluescript, 
respectively). The sequences of VH and VK were determined with an 
ALF DNA sequencer (Pharmacia, Uppsala, Sweden). Each V-gene 
was cloned and sequenced in both directions from two independent 
PCRs. 
2.3. Construction of scFv expression vectors 
The VH gene segment, excised with fis/EII and Pi/I, and the VK 
gene fragment, digested with Xhol and Sad, were subcloned into 
pscFv-D9D10 vector which has the c-myc tag at the carboxy-terminus 
of the scFv gene. This construct was named p3G12T. For the con-
struction of the scFv expression vector with the c-myc tag at the 
amino-terminus, the tag sequence was amplified by PCR with the 
primers (TAGNCOI: 5'-CCATGGCCGAACAAAAACTCATCT-
CAGAAGAGGATC-3' and TAGPSTI: 5'-CTGCAGCTGCACCT-
GATTCAGATCCTCTTCTGAG-3'; indicated restriction sites are 
underlined), cloned in pGEM-T and, after DNA sequence analysis, 
subcloned as a Ncol-PstI fragment into the NcollPstl sites of the 
pHENl vector. Recombinant clones were screened by PCR and veri-
fied by DNA sequence analysis. The correct construct was cut by 
Hindlll and Pstl and the fragment was subcloned into the pscFv-
D9D10-GF311 vector which does not contain a c-myc tag sequence. 
Finally, the resulting expression vector was cut by Pstl and Xhol and 
ligated with the 3G12 scFv gene as a Pstl-Xhol fragment and the 
correct clone was confirmed by DNA sequence analysis. The latter 
plasmid was called pT3G12. 
2.4. Expression, detection, purification and analysis of 3G12 scFv 
protein 
Plasmid DNAs of p3G12T and pT3G12 were transformed in Es-
cherichia coli JM83. The bacteria were grown at 30°C in LB medium 
(1% Bacto-tryptone, 0.5% yeast extract, 85 mM NaCl) with 100 μg/ml 
ampicillin and 1% glucose for 18 h. The culture was then diluted 1/20 
in LB plus ampicillin and 0.1% glucose and further grown at 30°C for 
2 h. Induction was performed with 0.1 mM IPTG before harvest 3 h 
later. The periplasmic extracts were prepared as described elsewhere 
[20]. The recombinant proteins were analyzed by SDS-PAGE and 
Western blotting and binding activity was assessed by ELISA. SDS-
PAGE (15% acrylamide) was performed as described by Laemmli [21]. 
For immunoblot analysis, proteins were transferred to PVDF filters 
(Millipore, Bedford, MA) in 25 mM Tris-glycine, pH 8.2, containing 
15% methanol. The filters were blocked with 1% casein in NT buffer 
(100 mM NaCl, 10 mM Tris-HCl, pH 7.5) at 4°C, washed twice with 
NT buffer and incubated with the 9E10 mAb (10 μg/ml) for 2 h at 
25°C. After washing the filters were incubated for 2 h at 25°C with an 
alkaline phosphatase-conjugated goat anti-mouse polyclonal 
IgG(H+L) (Jackson ImmunoResearch, West Grove, PA) as the sec-
ond Ab. Binding to scFv proteins was visualized with BCIP and NBT. 
For quantitation of scFv expression, the periplasmic extracts obtained 
from equivalent cultures were serially diluted and analyzed by West-
ern blotting and the amounts of scFv products estimated by compar-
ison with a dilution series of purified scFv. 
For the purification of scFv, periplasmic extracts were applied onto 
a 9E10 affinity column in equilibration buffer (50 mM Tris-HCl, 0.2 
M NaCl pH 7.5). The column was washed with 0.1 M citrate pH 5.0 
and the c-myc tag-containing Ig fragment was then eluted from the 
column with 0.1 M citrate pH 3.0. The eluted fractions were imme-
diately neutralized with 1 M Tris-HCl pH 9.O. The purity of the 
fractions was analyzed by SDS-PAGE and the concentration deter-
mined with the Bradford method [22], bovine serum albumin was used 
as a standard. 
2.5. ELISA for the determination of scFv binding to gelatinase B 
Detection of scFv binding to human gelatinase B was performed by 
ELISA. Pretreated 96-well microtiter plates (Maxisorp, Nunc, Ros-
kilde, Denmark) were coated overnight at 4°C with purified human 
gelatinase B [23] at 1 μ^piιΐ in 50 mM Tris-HCl, pH 8.5 (50 μΐ/well). 
After blocking for 1 h at 37°C with 200 μΐ/well of blocking buffer (50 
mM Tris-HCl, pH 7.4, 154 mM NaCl, 0.1% casein), the periplasmic 
extracts or purified scFv were incubated for 3 h at 37°C. After wash-
ing, the biotinylated anti-c-myc mAb 9E10 was added at 0.1 μg/ml in 
assay buffer (blocking buffer plus 0.05% Tween-20) and incubated for 
2 h at 37°C. Binding of biotinylated Ab was detected with streptavi-
din-peroxidase (Sigma) 0.1 μ^ηιΐ in assay buffer (50 μΐ/well) and the 
substrate tetramefhylbenzidine dihydrochloride (Aldrich; 1.8 mM in 
100 mM NaAcxitric acid, pH 4.9, 0.003% H 20 2) for 1 h at 37°C. The 
reaction was stopped by adding 2 M H2SO4 and the A450 was read 
spectrophotometrically. 
2.6. Inhibition of biological activity 
The inhibitory activity was determined as previously described 
[13,14]. Briefly, nasal septum collagen type II (Sigma) was heat-dena-
tured at 60°C for 20 min and incubated for 1 h with the purified 
enzyme and scFv in buffer containing 50 mM Tris-HCl pH 6.9, 
5 mM CaCl2, 0.1% Triton X-100 and 1 mM Pefabloc (Boehringer 
Mannheim, Germany). The reaction was stopped by adding SDS-
PAGE loading buffer to the mixture which was then run on a 7.5% 
SDS-PAGE gel under reducing conditions. Gels were stained with 
Coomassie brilliant blue. The neutralizing activity of scFv was de-
tected by the presence of remaining intact type II collagen. As con-
trols for gelatinase inhibition, the inhibitory REGA-3G12 monoclonal 
as well as a purified pepsin-treated F(ab')2 derivative and 1,10-phe-
nanthroline (Sigma Chemical Company, St. Louis, MO) were used. 
3. Results 
3.1. Cloning and sequencing of REG'A-3G12 VH and VK genes 
To obtain D N A fragments encoding the variable regions of 
the heavy and light chains of m A b REGA-3G12, total cellular 
R N A was isolated from hybridoma cells and transcribed into 
cDNA. The V H and V K fragments were subsequently ampli-
fied by P C R with primers covering the relatively conserved 
regions at the 5' and 3 ' ends of murine antibody variable 
domains and were inserted into pEG04 (Pstl/BstEll) and 
pBluescript SK (SacllXhol), respectively, and analyzed by 
D N A sequencing. The nucleotide and deduced amino acid 
sequences are shown in Fig. 1. Sequence comparison shows 
that the REGA-3G12 V H gene comprises 369 bp, encoding 
123 amino acids, and is a member of subgroup II (B) accord-
ing to the classification of Kaba t [24] with a long C D R 3 
containing 14 amino acid residues. The V K gene, 321 bp in 
size encoding 107 amino acids, belongs to the mouse VL 
group V. 
3.2. Expression of the scFv protein of REGA-3G12 in E. coli 
Initially, the expression vector p3G12T (Fig. 2A) was con-
structed by replacing the V H and V K sequences in the vector 
pscFv-D9D10 [18] with those derived from REGA-3G12. 
Correct clones were selected and after induction of the cul-
tures with 0.1 m M IPTG, the periplasmic fractions were pre-
pared. SDS-PAGE and immunoblot analysis demonstrated an 
induced 31 k D a band (Fig. 2B) and detection in ELISA con-
firmed the expression of a gelatinase B-binding antibody frag-
ment. However, the expression yields were < 0.2 mg/1 of cul-
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Fig. 1. Cloning of the variable fragments of the gelatinase B-inhibitory murine monoclonal REGA-3G12. Nucleotide and derived amino acid 
sequences of the VH (A) and the VK (B) encoding cDNA fragments of REGA-3G12 are shown. The hypervariable regions (CDR) are boxed 
and numbered. 
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Fig. 2. Expression in E. coli of single chain Fvs derived from 
REGA-3G12. A: Construction of the expression plasmids p3G12T 
and pT3G12. In both instances the VH and VK (VK) regions (see 
Fig. 1) were fused by a linker. The c-myc tag cDNA sequence (Tag) 
was inserted in front or at the 3'-end of the variable gene segments. 
In all vectors the lacZ and pelB sequences were at the 5'-end. B 
and C: Western blot analysis of the recombinant product from 
IPTG-induced cultures p3G12T and pT3G12, respectively. Lanes 1-
8 contain immunoreactive (anti-c-mjc) scFv from the equivalent of 
respectively 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 and 25.6 μΐ periplasmic 
fraction. Lane M shows a molecular size standardization expressed 
in kDa. 
ture. The VH-linker-VK sequence was then cloned into the 
pHENl expression vector in which the c-myc sequence was 
cloned so that the tag sequence is at the 5' end of the scFv 
gene (Fig. 2C). More than 3-fold higher yields were obtained 
with the newly constructed pT3G12 vector as compared with 
p3G12T, as demonstrated by analysis of dilution series of the 
periplasmic fractions (Fig. 2C). However, the purification of 
the scFv-T3G12 by affinity chromatography did not yield sig-
nificantly more scFv protein. 
[14] were isolated by RT-PCR, cloned and sequenced. Both 
VH and VK genes showed the typical characteristics of mouse 
V domains, i.e. each contained two cysteines for intramolec-
ular disulfide bridge formation and the distribution into 
framework (FR) and hypervariable (CDR) regions (Fig. 1). 
The relatively long CDR3 of the heavy chain (14 residues) 
indicates that the parent REGA-3G12 antibody is affinity ma-
tured. This is reflected in the high affinity of this antibody 
(K¿ = 2.1 X10 - 9 M). Two vectors were constructed for the 
inducible expression of scFv antibody fragments in E. coli 
and the recombinant products were purified and analyzed. 
The NH2-terminal c-myc tag allowed for the expression of 
higher yields, when compared with the scFv containing this 
tag at the carboxy-terminus. Replacement of the c-myc tag 
from the COOH- to the NH2-terminal end of the scFv gene 
was also observed to yield much higher antibody levels of a 
3.3. Inhibition of gelatinase B activity 
The gelatinase B-inhibitory activity of the scFv of REGA-
3G12 was compared with those of the intact monoclonal and 
a divalent F(ab')2 derivative. The latter was prepared by pep-
sin treatment of the intact monoclonal antibody. On the basis 
of protein concentrations, the scFv derivative 3G12T inhibited 
the enzymatic activity of purified gelatinase B on denatured 
type II collagen equally well as REGA-3G12 and the F(ab')2 
derivative (Fig. 3). 
4. Discussion 
The variable regions of the light and heavy chain genes of 
the gelatinase B-inhibitory monoclonal antibody REGA-3G12 
Fig. 3. Inhibition of gelatinase B activity by REGA-3G12 deriva-
tives The gelatinase B inhibition assay consists in the degradation of 
denatured nasal septum type II collagen substrate (S) by purified 
neutrophil gelatinase B (E) and inhibition by various substances. A: 
Lane 1: S; lane 2: S digested by E; lane 3: S and E and 1,10-phe-
nanthroline; lanes 4 and 5: S and E and, respectively 3 μg and 5 μg 
F(ab')2 (these F(ab')2 fragments were generated by pepsin-mediated 
clipping of the intact monoclonal REGA-3G12); lane 6: S and E 
and 5 μg intact REGA-3G12. HC and LC indicate light chain and 
heavy chain, respectively. The molecular standardization is indicated 
in kDa by arrows at the left side. B: Lanes 1 and 2 are the control 
reactions, as in A. Lanes 7, 8 and 9: S and E and, respectively, 
1 μg, 3 μg and 5 μg of scFv 3G12T. sC indicates the single-chain 
variable fragment. The molecular standardization is indicated in 
kDa. 
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scFv directed towards another antigen (G. Froyen, unpub-
lished results). 
Production of scFv in inclusion bodies and secretion of 
scFv in the periplasmic compartment were monitored by 
spot blot, SDS-PAGE and Western blot analyses (Fig. 2 
and data not shown), which showed that a considerable frac-
tion is not secreted. Correct folding of the recognition domain 
of the secreted REGA-3G12 antibody derivative was evi-
denced by ELISA and by inhibitory activity against the nat-
ural substrate. Because the neutralization titers of the scFv 
resemble those of the original antibody, it is reasonable to 
accept that the glycine-serine linker enables the folding of 
the covalently linked VH and VK domains in a correct way 
(Fig. 3 and data not shown). Recombinant Fv proteins might 
mimic the antigen binding site but they dissociate in vivo. In 
contrast, recombinant scFv are more stable in vivo [25]. 
In most instances, immunoglobulins do not possess N-
linked carbohydrates in the variable regions. Therefore, ex-
pression in bacteria will in such cases yield a product with 
unaltered antigenicity (due to TV-linked sugars) when com-
pared to expression in eukaryotic cells. 
Many scFv proteins have been engineered into immunocon-
jugates which are directed against cell surface molecules, e.g. 
tumor cell markers. The scFv of our study is directed against 
a functional secreted enzyme. Recently, a scFv with inhibitory 
activity against the secreted cytokine, IFN-γ, has been devel-
oped [18] and, alternatively, catalytic antibodies and deriva-
tives have been shown to possess intrinsic enzymatic activity. 
Our report demonstrates that an enzyme activity can readily 
be inhibited with scFv antibody fragments. In terms of metal-
loprotease-mediated catalysis, the availability of this scFv 
might enable further structural and functional studies of the 
active site of the enzyme. Additionally, the REGA-3G12 
scFvs may prove to be useful for the diagnosis and therapy 
of diseases with excessive or detrimental gelatinase B produc-
tion. 
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